|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
2
|
Hennessy BT, Coleman RL and Markman M:
Ovarian cancer. Lancet. 374:1371–1382. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Aleksandra Kujawa K and Lisowska KM:
Ovarian cancer - from biology to clinic. Postepy Hig Med Dosw
Online. 69:1275–1290. 2015.(In Polish). View Article : Google Scholar
|
|
4
|
Petrillo M, De Iaco P, Cianci S, Perrone
M, Costantini B, Ronsini C, Scambia G and Fagotti A: Long-term
survival for platinum-sensitive recurrent ovarian cancer patients
treated with secondary cytoreductive surgery plus hyperthermic
intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 23:1660–1665.
2016. View Article : Google Scholar
|
|
5
|
Dinkelspiel HE, Tergas AI, Zimmerman LA,
Burke WM, Hou JY, Chen L, Hillyer G, Neugut AI, Hershman DL and
Wright JD: Use and duration of chemotherapy and its impact on
survival in early-stage ovarian cancer. Gynecol Oncol. 137:203–209.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Husseinzadeh N: Status of tumor markers in
epithelial ovarian cancer has there been any progress? A review.
Gynecol Oncol. 120:152–157. 2011. View Article : Google Scholar
|
|
7
|
Banerjee S and Kaye S: The role of
targeted therapy in ovarian cancer. Eur J Cancer. 47(Suppl 3):
S116–S130. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gibson AJ, Krishnansu S, Tewari KS, Monk
BJ and Chase DM: updates on drug discovery in ovarian cancer.
Gynecol Oncol Res Pract. 1:32014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Modjtahedi H and Dean C: The receptor for
EGF and its ligands - expression, prognostic value and target for
therapy in cancer (Review). Int J Oncol. 4:277–296. 1994.PubMed/NCBI
|
|
10
|
Mendelsohn J and Baselga J: Epidermal
growth factor receptor targeting in cancer. Semin Oncol.
33:369–385. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Arteaga CL and Engelman JA: ERBB
receptors: From oncogene discovery to basic science to
mechanism-based cancer therapeutics. Cancer Cell. 25:282–303. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mass RD: The HER receptor family: A rich
target for therapeutic development. Int J Radiat Oncol Biol Phys.
58:932–940. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Roskoski R Jr: ErbB/HER protein-tyrosine
kinases: Structures and small molecule inhibitors. Pharmacol Res.
87:42–59. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Appert-Collin A, Hubert P, Crémel G and
Bennasroune A: Role of ErbB Receptors in Cancer Cell Migration and
Invasion. Front Pharmacol. 6:2832015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lafky JM, Wilken JA, Baron AT and Maihle
NJ: Clinical implications of the ErbB/epidermal growth factor (EGF)
receptor family and its ligands in ovarian cancer. Biochim Biophys
Acta. 1785:232–265. 2008.PubMed/NCBI
|
|
17
|
Ioannou N, Seddon AM, Dalgleish A,
Mackintosh D and Modjtahedi H: Expression pattern and targeting of
HER family members and IGF-IR in pancreatic cancer. Front Biosci
(Landmark Ed). 17:2698–2724. 2012. View
Article : Google Scholar
|
|
18
|
Khelwatty SA, Essapen S, Seddon AM and
Modjtahedi H: Prognostic significance and targeting of HER family
in colorectal cancer. Front Biosci (Landmark Ed). 18:394–421. 2013.
View Article : Google Scholar
|
|
19
|
Davies S, Holmes A, Lomo L, Steinkamp MP,
Kang H, Muller CY and Wilson BS: High incidence of ErbB3, ErbB4,
and MET expression in ovarian cancer. Int J Gynecol Pathol.
33:402–410. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Modjtahedi H, Ali S and Essapen S:
Therapeutic application of monoclonal antibodies in cancer:
Advances and challenges. Br Med Bull. 104:41–59. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Serrano-Olvera A, Dueñas-González A,
Gallardo-Rincón D, Candelaria M and De la Garza-Salazar J:
Prognostic, predictive and therapeutic implications of HER2 in
invasive epithelial ovarian cancer. Cancer Treat Rev. 32:180–190.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Langdon SP, Faratian D, Nagumo Y, Mullen P
and Harrison DJ: Pertuzumab for the treatment of ovarian cancer.
Expert Opin Biol Ther. 10:1113–1120. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sheng Q and Liu J: The therapeutic
potential of targeting the EGFR family in epithelial ovarian
cancer. Br J Cancer. 104:1241–1245. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kaye SB, Poole CJ, Dańska-Bidzińska A,
Gianni L, Del Conte G, Gorbunova V, Novikova E, Strauss A, Moczko
M, McNally VA, et al: A randomized phase II study evaluating the
combination of carboplatin-based chemotherapy with pertuzumab
versus carboplatin-based therapy alone in patients with relapsed,
platinum-sensitive ovarian cancer. Ann Oncol. 24:145–152. 2013.
View Article : Google Scholar
|
|
25
|
Dutta DK and Dutta I: Origin of ovarian
cancer: Molecular profiling. J Obstet Gynaecol India. 63:152–157.
2013. View Article : Google Scholar :
|
|
26
|
Reyes HD, Thiel KW, Carlson MJ, Meng X,
Yang S, Stephan JM and Leslie KK: Comprehensive profiling of
EGFR/HER receptors for personalized treatment of gynecologic
cancers. Mol Diagn Ther. 18:137–151. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bapat SA: Human ovarian cancer stem cells.
Reproduction. 140:33–41. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Walters Haygood CL, Arend RC, Straughn JM
and Buchsbaum DJ: Ovarian cancer stem cells: Can targeted therapy
lead to improved progression-free survival? World J Stem Cells.
6:441–447. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao J, Klausen C, Qiu X, Cheng JC, Chang
HM and Leung PC: Betacellulin induces Slug-mediated down-regulation
of E-cadherin and cell migration in ovarian cancer cells.
Oncotarget. Feb 22–2016.(Epub ahead of print). View Article : Google Scholar
|
|
30
|
Cunningham MP, Thomas H, Fan Z and
Modjtahedi H: Responses of human colorectal tumor cells to
treatment with the anti-epidermal growth factor receptor monoclonal
antibody ICR62 used alone and in combination with the EGFR tyrosine
kinase inhibitor gefitinib. Cancer Res. 66:7708–7715. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Khelwatty SA, Essapen S, Seddon AM and
Modjtahedi H: Growth response of human colorectal tumour cell lines
to treatment with afatinib (BIBW2992), an irreversible erbB family
blocker, and its association with expression of HER family members.
Int J Oncol. 39:483–491. 2011.PubMed/NCBI
|
|
32
|
Ioannou N, Dalgleish AG, Seddon AM,
Mackintosh D, Guertler U, Solca F and Modjtahedi H: Anti-tumour
activity of afatinib, an irreversible ErbB family blocker, in human
pancreatic tumour cells. Br J Cancer. 105:1554–1562. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Davis A, Tinker AV and Friedlander M:
‘Platinum resistant’ ovarian cancer: What is it, who to treat and
how to measure benefit? Gynecol Oncol. 133:624–631. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dinkelspiel HE, Champer M, Hou J, Tergas
A, Burke WM, Huang Y, Neugut AI, Ananth CV, Hershman DL and Wright
JD: Long-term mortality among women with epithelial ovarian cancer.
Gynecol Oncol. 138:421–428. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chase DM, Mathur N and Tewari KS: Drug
discovery in ovarian cancer. Recent Patents Anticancer Drug Discov.
5:251–260. 2010. View Article : Google Scholar
|
|
36
|
Bonneau C, Rouzier R, Geyl C, Cortez A,
Castela M, Lis R, Daraï E and Touboul C: Predictive markers of
chemoresistance in advanced stages epithelial ovarian carcinoma.
Gynecol Oncol. 136:112–120. 2015. View Article : Google Scholar
|
|
37
|
Wilken JA, Badri T, Cross S, Raji R,
Santin AD, Schwartz P, Branscum AJ, Baron AT, Sakhitab AI and
Maihle NJ: EGFR/HER-targeted therapeutics in ovarian cancer. Future
Med Chem. 4:447–469. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Roskoski R Jr: The ErbB/HER family of
protein-tyrosine kinases and cancer. Pharmacol Res. 79:34–74. 2014.
View Article : Google Scholar
|
|
39
|
Modjtahedi H, Khelwatty SA, Kirk RS,
Seddon AM, Essapen S, Del Vecchio CA, Wong AJ and Eccles S:
Immunohistochemical discrimination of wild-type EGFR from EGFRvIII
in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10. Br J
Cancer. 106:883–888. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Weroha SJ, Oberg AL, Ziegler KL, Dakhilm
SR, Rowland KM, Hartmann LC, Moore DF Jr, Keeney GL, Peethambaram
PP and Haluska P: Phase II trial of lapatinib and topotecan
(LapTop) in patients with platinum-refractory/resistant ovarian and
primary peritoneal carcinoma. Gynecol Oncol. 122:116–120. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lheureux S, Krieger S, Weber B, Pautier P,
Fabbro M, Selle F, Bourgeois H, Petit T, Lortholary A, Plantade A,
et al: Expected benefits of topotecan combined with lapatinib in
recurrent ovarian cancer according to biological profile: A phase 2
trial. Int J Gynecol Cancer. 22:1483–1488. 2012.PubMed/NCBI
|
|
42
|
Teplinsky E and Muggia F: Targeting HER2
in ovarian and uterine cancers: Challenges and future directions.
Gynecol Oncol. 135:364–370. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nimeiri HS, Oza AM, Morgan RJ, Friberg G,
Kasza K, Faoro L, Salgia R, Stadler WM, Vokes EE and Fleming GF;
Chicago Phase II Consortium; PMH Phase II Consortium; California
Phase II Consortium. Efficacy and safety of bevacizumab plus
erlotinib for patients with recurrent ovarian, primary peritoneal,
and fallopian tube cancer: A trial of the Chicago, PMH, and
California Phase II Consortia. Gynecol Oncol. 110:49–55. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pautier P, Joly F, Kerbrat P, Bougnoux P,
Fumoleau P, Petit T, Rixe O, Ringeisen F, Carrasco AT and Lhommé C:
Phase II study of gefitinib in combination with paclitaxel (P) and
carboplatin (C) as second-line therapy for ovarian, tubal or
peritoneal adenocarcinoma (1839IL/0074). Gynecol Oncol.
116:157–162. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Garcia AA, Sill MW, Lankes HA, Godwin AK,
Mannel RS, Armstrong DK, Carolla RL, Liepman MK, Spirtos NM,
Fischer EG, et al: A phase II evaluation of lapatinib in the
treatment of persistent or recurrent epithelial ovarian or primary
peritoneal carcinoma: A gynecologic oncology group study. Gynecol
Oncol. 124:569–574. 2012. View Article : Google Scholar
|
|
46
|
Vergote IB, Jimeno A, Joly F, Katsaros D,
Coens C, Despierre E, Marth C, Hall M, Steer CB, Colombo N, et al:
Randomized phase III study of erlotinib versus observation in
patients with no evidence of disease progression after first-line
platin-based chemotherapy for ovarian carcinoma: A European
Organisation for Research and Treatment of Cancer-Gynaecological
Cancer Group, and Gynecologic Cancer Intergroup study. J Clin
Oncol. 32:320–326. 2014. View Article : Google Scholar
|
|
47
|
Campos SM, Berlin ST, Parker LM, Chen WY,
Bunnell CA, Atkinson T, Lee J, Matulonis U, Hirsch MS, Harris L, et
al: Phase I trial of liposomal doxorubicin and ZD1839 in patients
with refractory gynecological malignancies or metastatic breast
cancer. Int J Clin Oncol. 15:390–398. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Davidson B and Tropé CG: Ovarian cancer:
Diagnostic, biological and prognostic aspects. Wom Health Lond.
10:519–533. 2014. View Article : Google Scholar
|
|
49
|
Au KK, Josahkian JA, Francis JA, Squire JA
and Koti M: Current state of biomarkers in ovarian cancer
prognosis. Future Oncol. 11:3187–3195. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Albini A, Bruno A, Gallo C, Pajardi G,
Noonan DM and Dallaglio K: Cancer stem cells and the tumor
microenvironment: Interplay in tumor heterogeneity. Connect Tissue
Res. 56:414–425. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Davidson B: Recently identified drug
resistance biomarkers in ovarian cancer. Expert Rev Mol Diagn.
16:569–578. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Bull Phelps SL, Schorge JO, Peyton MJ,
Shigematsu H, Xiang LL, Miller DS and Lea JS: Implications of EGFR
inhibition in ovarian cancer cell proliferation. Gynecol Oncol.
109:411–417. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Glaysher S, Bolton LM, Johnson P, Atkey N,
Dyson M, Torrance C and Cree IA: Targeting EGFR and PI3K pathways
in ovarian cancer. Br J Cancer. 109:1786–1794. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Viloria-Petit AM and Kerbel RS: Acquired
resistance to EGFR inhibitors: Mechanisms and prevention
strategies. Int J Radiat Oncol Biol Phys. 58:914–926. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Jones HE, Gee JM, Barrow D, Tonge D,
Holloway B and Nicholson RI: Inhibition of insulin receptor
isoform-A signalling restores sensitivity to gefitinib in
previously de novo resistant colon cancer cells. Br J Cancer.
95:172–180. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Mueller KL, Hunter LA, Ethier SP and
Boerner JL: Met and c-Src cooperate to compensate for loss of
epidermal growth factor receptor kinase activity in breast cancer
cells. Cancer Res. 68:3314–3322. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
van der Veeken J, Oliveira S, Schiffelers
RM, Storm G, van Bergen En Henegouwen PM and Roovers RC: Crosstalk
between epidermal growth factor receptor- and insulin-like growth
factor-1 receptor signaling: Implications for cancer therapy. Curr
Cancer Drug Targets. 9:748–760. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Tandon R, Kapoor S, Vali S, Senthil V,
Nithya D, Venkataramanan R, Sharma A, Talwadkar A, Ray A, Bhatnagar
PK, et al: Dual epidermal growth factor receptor
(EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: A
novel approach for overcoming resistance in anticancer treatment.
Eur J Pharmacol. 667:56–65. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ioannou N, Seddon AM, Dalgleish A,
Mackintosh D and Modjtahedi H: Treatment with a combination of the
ErbB (HER) family blocker afatinib and the IGF-IR inhibitor,
NVP-AEW541 induces synergistic growth inhibition of human
pancreatic cancer cells. BMC Cancer. 13:412013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Beltran PJ, Calzone FJ, Mitchell P, Chung
YA, Cajulis E, Moody G, Belmontes B, Li CM, Vonderfecht S,
Velculescu VE, et al: Ganitumab (AMG 479) inhibits IGF-II-dependent
ovarian cancer growth and potentiates platinum-based chemotherapy.
Clin Cancer Res. 20:2947–2958. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Filip S, English D and Mokrý J: Issues in
stem cell plasticity. J Cell Mol Med. 8:572–577. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Bellantuono I: Haemopoietic stem cells.
Int J Biochem Cell Biol. 36:607–620. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Trounson A: Stem cells, plasticity and
cancer - uncomfortable bed fellows. Development. 131:2763–2768.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhou Q, Chen A, Song H, Tao J, Yang H and
Zuo M: Prognostic value of cancer stem cell marker CD133 in ovarian
cancer: A meta-analysis. Int J Clin Exp Med. 8:3080–3088.
2015.PubMed/NCBI
|
|
66
|
Saito T and Mimori K: Cancer stemness and
circulating tumor cells. Nihon Rinsho. 73:806–810. 2015.(In
Japanese). PubMed/NCBI
|
|
67
|
Sacks JD and Barbolina MV: Expression and
function of CD44 in epithelial ovarian carcinoma. Biomolecules.
5:3051–3066. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Elzarkaa AA, Sabaa BE, Abdelkhalik D,
Mansour H, Melis M, Shaalan W, Farouk M, Malik E and Soliman AA:
Clinical relevance of CD44 surface expression in advanced stage
serous epithelial ovarian cancer: A prospective study. J Cancer Res
Clin Oncol. 142:949–958. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Su D, Deng H, Zhao X, Zhang X, Chen L,
Chen X, Li Z, Bai Y, Wang Y, Zhong Q, et al: Targeting CD24 for
treatment of ovarian cancer by short hairpin RNA. Cytotherapy.
11:642–652. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Burgos-Ojeda D, Wu R, McLean K, Chen YC,
Talpaz M, Yoon E, Cho KR and Buckanovich RJ: CD24+
ovarian cancer cells are enriched for cancer-initiating cells and
dependent on JAK2 signaling for growth and metastasis. Mol Cancer
Ther. 14:1717–1727. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Schilder RJ, Brady WE, Lankes HA, Fiorica
JV, Shahin MS, Zhou XC, Mannel RS, Pathak HB, Hu W, Alpaugh RK, et
al: Phase II evaluation of dasatinib in the treatment of recurrent
or persistent epithelial ovarian or primary peritoneal carcinoma: A
Gynecologic Oncology Group study. Gynecol Oncol. 127:70–74. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Konecny GE, Glas R, Dering J, Manivong K,
Qi J, Finn RS, Yang GR, Hong KL, Ginther C, Winterhoff B, et al:
Activity of the multikinase inhibitor dasatinib against ovarian
cancer cells. Br J Cancer. 101:1699–1708. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Teoh D, Ayeni TA, Rubatt JM, Adams DJ,
Grace L, Starr MD, Barry WT, Berchuck A, Murphy SK and Secord AA:
Dasatinib (BMS-35482) has synergistic activity with paclitaxel and
carboplatin in ovarian cancer cells. Gynecol Oncol. 121:187–192.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Xiao J, Xu M, Hou T, Huang Y, Yang C and
Li J: Dasatinib enhances antitumor activity of paclitaxel in
ovarian cancer through Src signaling. Mol Med Rep. 12:3249–3256.
2015.PubMed/NCBI
|
|
75
|
Secord AA, Teoh D, Jia J, Nixon AB, Grace
L, Adams DJ and Murphy SK: Dasatinib (BMS-35482) interacts
synergistically with docetaxel, gemcitabine, topotecan, and
doxorubicin in ovarian cancer cells with high SRC pathway
activation and protein expression. Int J Gynecol Cancer.
24:218–225. 2014. View Article : Google Scholar : PubMed/NCBI
|
